{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=epoetin+alfa&page=3", "query": { "intervention": "epoetin alfa", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 169, "total_pages": 17, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=epoetin+alfa&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=epoetin+alfa&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-05T22:25:03.366Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01235923", "title": "Randomized Study of Weekly Erythropoietin Dosing in Preterm Infants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Preterm Infants" ], "interventions": [ { "name": "three times weekly Epo", "type": "DRUG" }, { "name": "weekly Epo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of New Mexico", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "7 Days", "maximum_age": "100 Days", "sex": "ALL", "summary": "7 Days to 100 Days" }, "enrollment_count": 20, "start_date": "2006-04", "completion_date": "2009-12", "has_results": true, "last_update_posted_date": "2022-06-21", "last_synced_at": "2026-10-05T22:25:03.366Z", "location_count": 1, "location_summary": "Albuquerque, New Mexico", "locations": [ { "city": "Albuquerque", "state": "New Mexico" } ], "official_url": "https://clinicaltrials.gov/study/NCT01235923" }, { "nct_id": "NCT05564390", "title": "MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia", "Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm", "Acute Myeloid Leukemia Post Cytotoxic Therapy", "Acute Myeloid Leukemia, Myelodysplasia-Related", "Myelodysplastic Syndrome" ], "interventions": [ { "name": "Allogeneic Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Azacitidine", "type": "DRUG" }, { "name": "Best Practice", "type": "OTHER" }, { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "Chest Radiography", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Daunorubicin Hydrochloride", "type": "DRUG" }, { "name": "Decitabine and Cedazuridine", "type": "DRUG" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Emavusertib", "type": "BIOLOGICAL" }, { "name": "Enasidenib", "type": "DRUG" }, { "name": "Epoetin Alfa", "type": "BIOLOGICAL" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Gemtuzumab Ozogamicin", "type": "DRUG" }, { "name": "Gilteritinib", "type": "DRUG" }, { "name": "Liposome-encapsulated Daunorubicin-Cytarabine", "type": "DRUG" }, { "name": "Luspatercept", "type": "BIOLOGICAL" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Mutation Carrier Screening", "type": "PROCEDURE" }, { "name": "Olutasidenib", "type": "DRUG" }, { "name": "Placebo Administration", "type": "DRUG" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Total-Body Irradiation", "type": "RADIATION" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER", "BIOLOGICAL", "RADIATION" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2000, "start_date": "2024-06-18", "completion_date": "2029-05-15", "has_results": false, "last_update_posted_date": "2026-10-05", "last_synced_at": "2026-10-05T22:25:03.366Z", "location_count": 341, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 262 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05564390" }, { "nct_id": "NCT00338286", "title": "A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer", "Neoplasm Metastasis" ], "interventions": [ { "name": "Standard supportive care (packed RBC transfusion)", "type": "OTHER" }, { "name": "epoetin alfa + packed RBC transfusion", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "FEMALE", "summary": "18 Years to 99 Years · Female only" }, "enrollment_count": 2098, "start_date": "2006-03-02", "completion_date": "2017-01-31", "has_results": true, "last_update_posted_date": "2018-03-19", "last_synced_at": "2026-10-05T22:25:03.366Z", "location_count": 14, "location_summary": "Anaheim, California • Gainesville, Florida • Miami, Florida + 11 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "New Port Richey", "state": "Florida" }, { "city": "Rockledge", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00338286" }, { "nct_id": "NCT00002303", "title": "The Safety and Effectiveness of r-HuEPO in Patients With AIDS or Advanced AIDS-Related Complex (ARC) Who Are Anemic", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "HIV Infections", "Cytopenias" ], "interventions": [ { "name": "Epoetin alfa", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ortho Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2005-06-24", "last_synced_at": "2026-10-05T22:25:03.366Z", "location_count": 1, "location_summary": "Raritan, New Jersey", "locations": [ { "city": "Raritan", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002303" }, { "nct_id": "NCT00077623", "title": "A Study of Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Anemia" ], "interventions": [ { "name": "epoetin alfa or beta", "type": "DRUG" }, { "name": "methoxy polyethylene glycol-epoetin beta (Mircera)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 572, "start_date": "2004-03", "completion_date": "2005-09", "has_results": true, "last_update_posted_date": "2016-05-25", "last_synced_at": "2026-10-05T22:25:03.366Z", "location_count": 17, "location_summary": "Hot Springs, Arkansas • Los Angeles, California • Riverside, California + 14 more", "locations": [ { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Riverside", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Jose", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00077623" }, { "nct_id": "NCT00386152", "title": "A Study Comparing Two Different PROCRIT Doses to a Dose of ARANESP in Anemic Cancer Patients Receiving Chemotherapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neoplasms", "Anemia", "Cancer" ], "interventions": [ { "name": "epoetin alfa", "type": "DRUG" }, { "name": "darbepoetin alfa", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Johnson & Johnson Pharmaceutical Research & Development, L.L.C.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 235, "start_date": "2006-11", "completion_date": "2008-05", "has_results": true, "last_update_posted_date": "2013-07-19", "last_synced_at": "2026-10-05T22:25:03.366Z", "location_count": 76, "location_summary": "Glendale, Arizona • Jonesboro, Arkansas • Little Rock, Arkansas + 73 more", "locations": [ { "city": "Glendale", "state": "Arizona" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Bakersfield", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00386152" }, { "nct_id": "NCT02064426", "title": "Long Term Extension Study for the Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anemia", "Renal Insufficiency, Chronic" ], "interventions": [ { "name": "Molidustat (BAY85-3934)", "type": "DRUG" }, { "name": "Epoetin alfa/beta", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 88, "start_date": "2014-03-13", "completion_date": "2016-11-16", "has_results": false, "last_update_posted_date": "2019-09-20", "last_synced_at": "2026-10-05T22:25:03.366Z", "location_count": 23, "location_summary": "Azusa, California • Long Beach, California • Lynwood, California + 16 more", "locations": [ { "city": "Azusa", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Lynwood", "state": "California" }, { "city": "Northridge", "state": "California" }, { "city": "San Dimas", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02064426" }, { "nct_id": "NCT02648347", "title": "Study to Evaluate Vadadustat for the Correction of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Anemia", "Non-Dialysis-Dependent Chronic Kidney Disease" ], "interventions": [ { "name": "Vadadustat", "type": "DRUG" }, { "name": "Darbepoetin alfa", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Akebia Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1751, "start_date": "2015-12", "completion_date": "2020-07-31", "has_results": true, "last_update_posted_date": "2022-06-27", "last_synced_at": "2026-10-05T22:25:03.366Z", "location_count": 208, "location_summary": "Huntsville, Alabama • Tuscumbia, Alabama • Glendale, Arizona + 148 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Tuscumbia", "state": "Alabama" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02648347" }, { "nct_id": "NCT00436748", "title": "Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Anemia", "Chronic Kidney Disease", "Kidney Disease" ], "interventions": [ { "name": "Darbepoetin Alfa", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "18 Years", "sex": "ALL", "summary": "1 Year to 18 Years" }, "enrollment_count": 116, "start_date": "2008-09-16", "completion_date": "2014-03-03", "has_results": true, "last_update_posted_date": "2022-11-29", "last_synced_at": "2026-10-05T22:25:03.366Z", "location_count": 42, "location_summary": "Birmingham, Alabama • Los Angeles, California • San Diego, California + 36 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00436748" }, { "nct_id": "NCT00053001", "title": "Thalidomide and Epoetin Alfa in Treating Anemia in Patients With Myelodysplastic Syndrome", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anemia", "Leukemia", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Neoplasms" ], "interventions": [ { "name": "epoetin alfa", "type": "BIOLOGICAL" }, { "name": "thalidomide", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Fallon Clinic", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": null, "start_date": "2001-06", "completion_date": "2007-10", "has_results": false, "last_update_posted_date": "2013-06-26", "last_synced_at": "2026-10-05T22:25:03.366Z", "location_count": 2, "location_summary": "Worcester, Massachusetts", "locations": [ { "city": "Worcester", "state": "Massachusetts" }, { "city": "Worcester", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00053001" } ] }